increases the model R square by 75% with P [ 0.0245. For predicting GS 7-10 cancer, addition of WA ancestry to the base model improves R square by 72% with P [ 0.0238. Thus when considered in combination with age, PSA and prostate size, % WA ancestry remained a strong predictor of both PrCa diagnosis and GS 7-10 cancer on biopsy.
INTRODUCTION AND OBJECTIVES: mpMRI and new biomarkers have emerged as popular alternatives prior to prostate biopsy (Bx). We sought to investigate a combination of 4Kscore and mpMRI to improve diagnostic performance, and potentially further reduce Bx rates compared to the individual tests alone METHODS: This was a retrospective, five-center study of men who underwent a 4Kscore, mpMRI, and Bx. Results from mpMRI were reported using PIRADS and categorized into low (PIRADS 1-2), intermediate (PIRADS 3) and high (Fig. 1) .
RESULTS: The final cohort included 407 men, of which 114 were found to have a HG cancer. Using a 4Kscore or MRI alone, resulted in a 25-27% biopsy reduction, with 8-12 men having an undetected HG. Combination strategies yielded higher specificities, leading to larger biopsy reductions in the range of 38-41%, while 11-15 men had an undetected HG. Sensitivity and NPV did not appreciably differ between strategies (Table 1) . Similar results were found in the category of men with a PSA of 2-10 and 3-10 ng/mL. CONCLUSIONS: Combining 4Kscore and mpMRI to make prostate Bx decisions could further reduce Bx rates, while improving specificity for high-grade cancer, with minimal changes to NPV and sensitivity Evidence for an effect of ASA on PCa is conflicting. The exact interaction pathways between ASA and carcinogenesis are still to be established. The aim of the study was to analyze the influence of ASA intake on PSA values and PCa development.
METHODS: A population-based analysis including 4314 men from the European Randomized Study of Screening for Prostate Cancer (ERSPC) database was conducted. Data about drug intake, age, family history and symptoms was obtained by a self-administered questionnaire. A transrectal ultrasound guided prostate biopsy was performed in men with a PSA-level > 3 ng/ml. Tumor stage and grade were registered; incidence and mortality data were obtained through registry linkages. PCa incidence and grade, total PSA value, free-to-total PSA and overall survival were compared between ASA users and non-users, respectively. RESULTS: Median follow-up time was 9.6 years. In all, n [ 789 (18.3%) men used aspirin [ASAþ] . Although overall PCa incidence was significantly lower among aspirin users ([ASAþ] 54 (6.8%) vs. [ASA-] 338 (9.6%), p 0.015), the multivariate cox-regression analysis did not show the decreased risk to be diagnosed with PCa ([ASAþ] hazard ratio (HR) 0.84, 95% confidence interval (CI) 0.62 -1.16; p [ 0.297) to be statistically significant. Total PSA values were significantly lower in aspirin users for both baseline (1.6 vs. 1.8 ng/ml, p [ 0.007) and
